L-744832-生命科學(xué)試劑-MCE_第1頁(yè)
L-744832-生命科學(xué)試劑-MCE_第2頁(yè)
L-744832-生命科學(xué)試劑-MCE_第3頁(yè)
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

Hotline:400-820-3792Inhibitors ? ScreeningLibraries ? Proteinswww.MedChemEL-744832Cat.No.:HY-116428CASNo.:160141-09-3分子式:C??H??N?O?S?分子量:559.78作用靶點(diǎn):FarnesylTransferase;Ras;TGF-βReceptor;Apoptosis作用通路:MetabolicEnzyme/Protease;GPCR/GProtein;MAPK/ERKPathway;TGF-beta/Smad;Apoptosis儲(chǔ)存方式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY生物活性L-744832是一種法尼基轉(zhuǎn)移酶(FarnesylTransferase)抑制劑。L-744,832能有效抑制H-Ras和N-Ras的法尼基化,但對(duì)K-Ras的處理影響較小。L-744,832不僅通過(guò)抑制Ras法尼基化直接靶向致癌通路,更通過(guò)表觀遺傳重編程恢復(fù)TGF-β信號(hào),從而增強(qiáng)放療敏感性。L-744832可誘導(dǎo)細(xì)胞周期阻滯并誘導(dǎo)細(xì)胞凋亡(apoptosis)。L-744832可用于胰腺癌等Ras驅(qū)動(dòng)型腫瘤的聯(lián)合治療研究。IC50&TargetH-RasNRASrG4體外研究L-744832(0.1-50μM,24-72h)showssignificantdifferencesinsensitivityinPanc-1,Capan-2,BxPC-3,AsPC-1andCFPAC-1cellswithIC50sof1.3,2.1,12.3,14.3and>50μM[1].L-744832(0.1-50μM,72h)arrestthesensitivecelllines(Panc-1,Capan-2,BxPC-3andAsPC-1)intheG2/MphaseofthecellcycleandthearrestoccursduringthemitoticentrystagedownstreamoftheG2/Mcheckpoint[1].L-744832(10μM,24-72h)inducesabovefivetypesofcellapoptosis,andthecombinationofradiotherapycansignificantlyincreasetheapoptosisrateofMIAPaCa-2cells,whilethiseffectisnotobservedinBxPC-3cells[1][2].L-744832(0.1-10μM)withionizingradiationresultsinenhancedcytotoxicityinhumanpancreaticcancercells[1].L-744832(5-10μM)effectivelyinhibitsthefarnesylationofH-RasandN-RasandMIAPaCa-2cellsaremoresensitivethanBxPC-3cells[2].L-744832(5-10μM,3-6h)restorestheexpressionofTGF-βtypeIIreceptor(RII)throughregulatingDNMT1,therebyre-establishingthetumor-suppressingfunctionofTGF-β[2].CellCycleAnalysis[2]1/3 MasterofBioactiveMolecules—您身邊的抑制劑大師www.MedChemECellLine:Panc-1,Capan-2,BxPC-3,AsPC-1andCFPAC-1cellsConcentration:0.1,0.5,1,10,25and50μMIncubationTime:72hResult:Dose-dependentincreasedinG2/MphaseaccumulationandtheproportionofG2/MphasecellsinPanc-1cellsincreasednearlythreefold.ApoptosisAnalysis[2]CellLine:Panc-1,Capan-2,BxPC-3,AsPC-1andCFPAC-1cellsConcentration:10μMIncubationTime:72hResult:Showedchromatincondensationandnuclearfragmentation.Increasedtheapoptoticindexineachgroup,andthisoccurredinbothwild-typep53(Capan-2)cellsandmutantp53(Panc-1)cells.WesternBlotAnalysis[2]CellLine:Panc-1,Capan-2,BxPC-3,AsPC-1andCFPAC-1cellsConcentration:10μMIncubationTime:72hResult:SignificantlyincreasedtheactivityofCyclinB1/Cdc2kinase.RT-PCR[1]CellLine:MIAPaCa-2cellsConcentration:10μMIncubationTime:3and6hResult:ActivatedtheRIIpromotertoincreaseitsmRNAlevels.ReducedthemRNAlevelsofDNMT1.WesternBlotAnalysis[1]CellLine:MIAPaCa-2cellsConcentration:10μMIncubationTime:3and6h2/3 MasterofBioactiveMolecules—您身邊的抑制劑大師www.MedChemEResult: ActivatedtheRIIpromotertoincreaseitsproteinlevels.ReducedtheproteinlevelsofDNMT1.REFERENCESSongSY,etal.K-Ras-independenteffectsofthefarnesyltransferaseinhibitorL-744,832oncyclinB1/Cdc2kinaseactivity,G2/Mcellcycleprogressionandapoptosisinhumanpancreaticductaladenocarcinomacells.Neoplasia.2000May-Jun;2(3):261-72.AlcockRA,etal.Farnesyltransferaseinhibitor(L-744,832)restoresTGF-betatypeIIreceptorexpressionandenhancesradiationsensitivityinK-rasmutantpancreaticcancercelllineMIAPaCa-2.Oncogene.2002Nov7;21(51):7883-90.McePdfHeightCaution:Producthasno

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論